-
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state Mol. Cancer (IF 37.3) Pub Date : 2023-11-29 Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels, Jan Tavernier
Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that local delivery of a bispecific Clec9A-PD-L1 targeted type I interferon (AcTaferon, AFN) overcomes this hurdle by reshaping the tumor immune landscape. Treatment with the bispecific AFN resulted
-
Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors Mol. Cancer (IF 37.3) Pub Date : 2023-11-28 Pere Llinàs-Arias, Miquel Ensenyat-Mendez, Sandra Íñiguez-Muñoz, Javier I. J. Orozco, Betsy Valdez, Matthew P. Salomon, Chikako Matsuba, Maria Solivellas-Pieras, Andrés F. Bedoya-López, Borja Sesé, Anja Mezger, Mattias Ormestad, Fernando Unzueta, Siri H. Strand, Alexander D. Boiko, E Shelley Hwang, Javier Cortés, Maggie L. DiNome, Manel Esteller, Mathieu Lupien, Diego M. Marzese
Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which is the first step of the metastatic process. We combined RNA expression and chromatin interaction data to identify insulator
-
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy Mol. Cancer (IF 37.3) Pub Date : 2023-11-28 Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, Hamidreza Kabiri, Hosein Salehian-Dehkordi, Mohammad Abdolvand, Sharareh Salmanizadeh, Mohsen Rashidi, Anoosha Niazmand, Saba Ahmadi, Sara Feizbakhshan, Saber Kabiri, Nasimeh Vatandoost, Tayebeh Ranjbarnejad
The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenced by genetic, epigenetic, and environmental factors. iPSCs offer a distinctive platform for investigating the origin of cancer, paving the way for novel approaches to cancer treatment, drug testing
-
The University of Kansas Cancer Center (KUCC), an NCI designated comprehensive cancer center Mol. Cancer (IF 37.3) Pub Date : 2023-11-28 Weijing Sun, Natalie Streeter, Joseph McGuirk, Roy Jensen
The University of Kansas Cancer Center is a National Cancer Institute-designated comprehensive cancer center. It is the only such designated cancer center in the state of Kansas. The cancer center’s mission, through its innovative approach to drug discovery, delivery, and development, is to transform cancer research and clinical care delivered in Kansas and western Missouri. KU Cancer Center operates
-
Exploiting innate immunity for cancer immunotherapy Mol. Cancer (IF 37.3) Pub Date : 2023-11-27 Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai, Kongming Wu
Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosuppressive signaling with immune checkpoint blockade, or enhancing immunostimulatory signaling with bispecific T cell engager and chimeric antigen receptor (CAR)-T cell. Although these agents have
-
CDK5: an oncogene or an anti-oncogene: location location location Mol. Cancer (IF 37.3) Pub Date : 2023-11-23 Kumar Nikhil, Kavita Shah
Recent studies have uncovered various physiological functions of CDK5 in many nonneuronal tissues. Upregulation of CDK5 and/or its activator p35 in neurons promotes healthy neuronal functions, but their overexpression in nonneuronal tissues is causally linked to cancer of many origins. This review focuses on the molecular mechanisms by which CDK5 recruits diverse tissue-specific substrates to elicit
-
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer Mol. Cancer (IF 37.3) Pub Date : 2023-11-18 Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai, Takeshi Tsutsumi, Kohei Taniguchi, Tomohito Tanaka, Kiyoshi Takahara, Tsuyoshi Konuma, Teruo Inamoto, Yoshinobu Hirose, Fumihito Ono, Yuichi Shiraishi
Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA). A multi-omics analysis on 389 BLCA and 35 adjacent normal tissues from a cohort of OMPU-NCC Consortium Japan was retrospectively performed by integrating the whole-exome and RNA-sequence dataset
-
ELF5 drives angiogenesis suppression though stabilizing WDTC1 in renal cell carcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-11-18 Tushuai Li, Longjiang Xu, Zhe Wei, Shaomei Zhang, Xingyu Liu, Yanzi Yang, Yue Gu, Jie Zhang
Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Angiogenesis is a main contributing factor for tumorigenesis. E74-like transcription factor 5 (ELF5) has been verified to participate in the progression of different cancers and can regulate angiogenesis. This study was aimed to explore the functions of ELF5 in RCC. Bioinformatics tools were used to predict the expression
-
Outsmarting trogocytosis to boost CAR NK/T cell therapy Mol. Cancer (IF 37.3) Pub Date : 2023-11-16 Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown, Hamid Reza Mirzaei
Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review, we explore the role of trogocytosis in CAR NK/T cell
-
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better Mol. Cancer (IF 37.3) Pub Date : 2023-11-14 Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger
Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects of this three-drug regimen in anti-PD-1-resistant melanoma. We employed a Simon’s two-stage design and analyzed circulating
-
Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis Mol. Cancer (IF 37.3) Pub Date : 2023-11-13 Nikolas H. Stoecklein, Georg Fluegen, Rosa Guglielmi, Rui P.L. Neves, Thilo Hackert, Emrullah Birgin, Stefan A. Cieslik, Monica Sudarsanam, Christiane Driemel, Guus van Dalum, André Franken, Dieter Niederacher, Hans Neubauer, Tanja Fehm, Jutta M. Rox, Petra Böhme, Lena Häberle, Wolfgang Göring, Irene Esposito, Stefan A. Topp, Frank A.W. Coumans, Jürgen Weitz, Wolfram T. Knoefel, Johannes C. Fischer
The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detection methodologies. This study sought to amplify assay-sensitivity by employing diagnostic leukapheresis (DLA) to screen large blood volumes. Sixty patients were subjected to DLA, with a median
-
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy Mol. Cancer (IF 37.3) Pub Date : 2023-11-11 Tatjana Sauerer, Giuliano Filippini Velázquez, Christoph Schmid
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in failure of normal hematopoiesis and life-threating cytopenia. Allogeneic hematopoietic stem cell transplantation (allo-HCT) is an established therapy with curative potential. Nevertheless, post-transplant relapse is common and
-
CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis Mol. Cancer (IF 37.3) Pub Date : 2023-11-06 Yumeng Cui, Xiaojie Wu, Jie Jin, Weiling Man, Jie Li, Xiang Li, Yanghua Li, He Yao, Rongbin Zhong, Shiyun Chen, Jiahui Wu, Tianhao Zhu, Yanli Lin, Junjie Xu, Youliang Wang
Noncoding RNAs such as circular RNAs (circRNAs) are abundant in the human body and influence the occurrence and development of various diseases. Non-small cell lung cancer (NSCLC) is one of the most common malignant cancers. Information on the functions and mechanism of circRNAs in lung cancer is limited; thus, the topic needs more exploration. The purpose of this study was to identify aberrantly expressed
-
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid Mol. Cancer (IF 37.3) Pub Date : 2023-11-06 Cyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, Damien Vasseur, Audrey Le Formal, Laure Chardin, Elisa Yaniz, Sébastien Gouy, Amandine Maulard, Stéphanie Scherier, Claire Sanson, Ludovic Lacroix, Sophie Cotteret, Lea Mauny, François Zaccarini, Etienne Rouleau, Alexandra Leary
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15–19% of cases. Peritoneal fluid, available in > 95% of advanced EOC cases, could serve as an alternative source of cell-free tumor DNA (cftDNA)
-
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia Mol. Cancer (IF 37.3) Pub Date : 2023-11-06 Ji Eun Shin, Soo-Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung-Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han-Woong Lee, Heon Yung Gee, Seunghee Hong, Kun-Liang Guan, Jae-Seok Roe, Hyunbeom Lee, Dong-Wook Kim, Hyun Woo Park
Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challenge. Here, we reposition FLT3, one of the most frequently mutated drivers of acute myeloid leukemia (AML), as a prognostic marker and therapeutic target of BP-CML. We generated
-
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study Mol. Cancer (IF 37.3) Pub Date : 2023-11-04 Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, Mariella Spalato-Ceruso, Mihaela Aldea, Damien Vasseur, Melissa Alame, Laura Blouin, Isabelle Soubeyran, Claudio Nicotra, Maud Ngocamus, Antoine Hollebecque, Yohann Loriot, Benjamin Besse, Ludovic Lacroix, Etienne Rouleau, Fabrice Barlesi, Fabrice Andre, Antoine Italiano
Despite the effectiveness of the various targeted therapies currently approved for solid tumors, acquired resistance remains a persistent problem that limits the ultimate effectiveness of these treatments. Polyclonal resistance to targeted therapy has been described in multiple solid tumors through high-throughput analysis of multiple tumor tissue samples from a single patient. However, biopsies at
-
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy Mol. Cancer (IF 37.3) Pub Date : 2023-10-30 Martina S. J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan
Correction: Mol Cancer 13, 157 (2014) https://doi.org/10.1186/1476-4598-13-157 Following publication of the original article [1], a reader reported that “two signals in Fig. 3C seem to be unexpectedly similar”, and as original blots are no longer available (only cropped versions of the triplicate blots), an alternative replicate of the Fig. 3c blot is provided in this correction. This replacement does
-
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-10-26 Liangliang Xu, Peng Wang, Li Li, Lian Li, Yang Huang, Yanfang Zhang, Xiaobo Zheng, Pengsheng Yi, Ming Zhang, Mingqing Xu
Vascular invasion is a major route for intrahepatic and distant metastasis in hepatocellular carcinoma (HCC) and is a strong negative prognostic factor. Circular RNAs (circRNAs) play important roles in tumorigenesis and metastasis. However, the regulatory functions and underlying mechanisms of circRNAs in the development of vascular invasion in HCC are largely unknown. High throughput sequencing was
-
Correction: CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling Mol. Cancer (IF 37.3) Pub Date : 2023-10-23 Tao Xie, Du-jiang Fu, Zhi-min Li, Dao-jun Lv, Xian-Lu Song, Yu-zhong Yu, Chong Wang, Kang-jin Li, Baoqian Zhai, Jiacheng Wu, Ning-Han Feng, Shan-Chao Zhao
Correction: Mol Cancer 21, 173 (2022) https://doi.org/10.1186/s12943-022-01630-9 Following publication of the original article [1], the authors requested to update the figures as stated below. We request to replace the misused image in C4-2 cells (sh-circ group) in Fig. 3H with the correct image which produced in May 26, 2021 when we conducted the experiment. We request to replace the misused images
-
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer Mol. Cancer (IF 37.3) Pub Date : 2023-10-18 Zhen Zeng, Minyang Fu, Yuan Hu, Yuquan Wei, Xiawei Wei, Min Luo
Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their behavior is regulated through a complex interplay of networks, including transcriptional, post-transcriptional, epigenetic, tumor microenvironment (TME), and epithelial-mesenchymal transition (EMT) factors. Numerous signaling
-
The strategies to cure cancer patients by eradicating cancer stem-like cells Mol. Cancer (IF 37.3) Pub Date : 2023-10-18 Yansui Mai, Jiyan Su, Chuan Yang, Chenglai Xia, Liwu Fu
Cancer stem-like cells (CSCs), a subpopulation of cancer cells, possess remarkable capability in proliferation, self-renewal, and differentiation. Their presence is recognized as a crucial factor contributing to tumor progression and metastasis. CSCs have garnered significant attention as a therapeutic focus and an etiologic root of treatment-resistant cells. Increasing evidence indicated that specific
-
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment Mol. Cancer (IF 37.3) Pub Date : 2023-10-13 Chenxi Ma, Chengzhe Yang, Ai Peng, Tianyong Sun, Xiaoli Ji, Jun Mi, Li Wei, Song Shen, Qiang Feng
Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population that plays a crucial role in remodeling the tumor microenvironment (TME). Here, through the integrated analysis of spatial and single-cell transcriptomics data across six common cancer types, we identified four distinct functional subgroups of CAFs and described their spatial distribution characteristics. Additionally, the analysis
-
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation Mol. Cancer (IF 37.3) Pub Date : 2023-10-09 Mohammad Chehelgerdi, Matin Chehelgerdi, Omer Qutaiba B. Allela, Renzon Daniel Cosme Pecho, Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Mohamed J. Saadh, Ayesha Amajd, Mabrouk A. Abo-Zaid, Roxana Yolanda Castillo-Acobo, Ahmed H. Ismail, Ali H. Amin, Reza Akhavan-Sigari
The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targeting techniques, which offer renewed hope for cancer patients. While several nanocarriers for medicinal purposes have been approved for human trials, only a few have been authorized for clinical
-
Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches Mol. Cancer (IF 37.3) Pub Date : 2023-10-06 Nazeer Hasan, Arif Nadaf, Mohammad Imran, Umme Jiba, Afsana Sheikh, Waleed H. Almalki, Salem Salman Almujri, Yousuf Hussain Mohammed, Prashant Kesharwani, Farhan Jalees Ahmad
Skin cancer is a global threat to the healthcare system and is estimated to incline tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is curable at an early stage, novel drug identification, clinical success, and drug resistance is another major challenge. To bridge the gap and bring effective treatment, it is important to understand the etiology of skin carcinoma
-
Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation Mol. Cancer (IF 37.3) Pub Date : 2023-10-06 Kangchun Wang, Xin Wang, Qi Pan, Bei Zhao
Pancreatic cancer (PC) is one of the most common malignancies. Surgical resection is a potential curative approach for PC, but most patients are unsuitable for operations when at the time of diagnosis. Even with surgery, some patients may still experience tumour metastasis during the operation or shortly after surgery, as precise prognosis evaluation is not always possible. If patients miss the opportunity
-
Retraction Note: m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5 Mol. Cancer (IF 37.3) Pub Date : 2023-10-06 Yi Zhang, Min Kang, Bin Zhang, Fanchao Meng, Jun Song, Hiroshi Kaneko, Fumio Shimamoto, Bo Tang
Retraction note: Mol Cancer 18, 185 (2019) https://doi.org/10.1186/s12943-019-1116-x The Editor in Chief has retracted this article after concerns were raised about potential image overlap in Figs. 1 and 6. Therefore, the Editor has lost confidence in the data presented here. None of the authors has responded to any correspondence from the editor/publisher about this retraction. Partial image overlap
-
ERK mediates interferon gamma-induced melanoma cell death Mol. Cancer (IF 37.3) Pub Date : 2023-10-06 Ameya Champhekar, Rachel Heymans, Justin Saco, Guillem Turon Font, Cynthia Gonzalez, Anne Gao, John Pham, June Lee, Ryan Maryoung, Egmidio Medina, Katie M. Campbell, Daniel Karin, David Austin, Robert Damioseaux, Antoni Ribas
Interferon-gamma (IFNγ) exerts potent growth inhibitory effects on a wide range of cancer cells through unknown signaling pathways. We pursued complementary screening approaches to characterize the growth inhibition pathway. We performed chemical genomics and whole genome targeting CRISPR/Cas9 screens using patient-derived melanoma lines to uncover essential nodes in the IFNγ-mediated growth inhibition
-
A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-10-06 Si-Cho Kim, Da-Won Kim, Eun Ju Cho, Jin-Young Lee, Jiwon Kim, Chaesun Kwon, Jeongsil Kim-Ha, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Won Kim, Woojin Kim, Hyunsoo Kim, Yoon Jun Kim, Jung-Hwan Yoon, Su Jong Yu, Young-Joon Kim
To address the shortcomings of current hepatocellular carcinoma (HCC) surveillance tests, we set out to find HCC-specific methylation markers and develop a highly sensitive polymerase chain reaction (PCR)-based method to detect them in circulating cell-free DNA (cfDNA). The analysis of large methylome data revealed that Ring Finger Protein 135 (RNF135) and Lactate Dehydrogenase B (LDHB) are universally
-
LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter Mol. Cancer (IF 37.3) Pub Date : 2023-10-04 Meijian Liao, Xiaolin Sun, Wendan Zheng, Mengdi Wu, Yifan Wang, Jia Yao, Yu Ma, Shoucui Gao, Dongsheng Pei
Lysine crotonylation (Kcr) is up-regulation in colorectal cancer (CRC) tissues, while its specific contribution remains uncertain. This study aimed to elucidate the role and mechanism of crotonylation on Lys27 of histone H3 (H3K27cr) in facilitating CRC metastasis. Immunohistochemistry was employed to investigate the correlation between H3K27cr and CRC metastasis. Both in vitro and in vivo assays employing
-
Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures Mol. Cancer (IF 37.3) Pub Date : 2023-10-03 Sandy Figiel, Wencheng Yin, Dimitrios Doultsinos, Andrew Erickson, Ninu Poulose, Reema Singh, Anette Magnussen, Thineskrishna Anbarasan, Renuka Teague, Mengxiao He, Joakim Lundeberg, Massimo Loda, Clare Verrill, Richard Colling, Pelvender S. Gill, Richard J. Bryant, Freddie C. Hamdy, Dan J. Woodcock, Ian G. Mills, Olivier Cussenot, Alastair D. Lamb
Genetic signatures have added a molecular dimension to prognostics and therapeutic decision-making. However, tumour heterogeneity in prostate cancer and current sampling methods could confound accurate assessment. Based on previously published spatial transcriptomic data from multifocal prostate cancer, we created virtual biopsy models that mimic conventional biopsy placement and core size. We then
-
Profiling small RNAs in fecal immunochemical tests: is it possible? Mol. Cancer (IF 37.3) Pub Date : 2023-10-03 Einar Birkeland, Giulio Ferrero, Barbara Pardini, Sinan U. Umu, Sonia Tarallo, Sara Bulfamante, Geir Hoff, Carlo Senore, Trine B Rounge, Alessio Naccarati
Fecal microRNAs represent promising molecules with potential clinical interest as non-invasive diagnostic and prognostic biomarkers. Colorectal cancer (CRC) screening based on the fecal immunochemical test (FIT) is an effective tool for prevention of cancer development. However, due to the poor sensitivity of FIT especially for premalignant lesions, there is a need for implementation of complementary
-
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics Mol. Cancer (IF 37.3) Pub Date : 2023-10-03 Kavita R. Gajbhiye, Rajesh Salve, Mahavir Narwade, Afsana Sheikh, Prashant Kesharwani, Virendra Gajbhiye
Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hybrid nanoparticles (LPHNPs) are advanced core–shell nanoconstructs with a polymeric core region enclosed by a lipidic layer, presumed to be derived from both liposomes and polymeric nanounits.
-
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials Mol. Cancer (IF 37.3) Pub Date : 2023-10-02 Hao Zhang, Xinghai Yue, Zhe Chen, Chao Liu, Wantao Wu, Nan Zhang, Zaoqu Liu, Liping Yang, Qing Jiang, Quan Cheng, Peng Luo, Guodong Liu
Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal component of the tumor microenvironment. The versatility and sophisticated mechanisms of CAFs in facilitating cancer progression have been elucidated extensively, including promoting cancer angiogenesis
-
EYA4 promotes breast cancer progression and metastasis through its role in replication stress avoidance Mol. Cancer (IF 37.3) Pub Date : 2023-09-30 Bárbara de la Peña Avalos, Romain Tropée, Pascal H. G. Duijf, Eloïse Dray
The Eyes Absent (EYA) family of proteins is an atypical group of four dual-functioning protein phosphatases (PP), which have been linked to many vital cellular processes and organogenesis pathways. The four family members of this PP family possess transcriptional activation and phosphatase functions, with serine/threonine and tyrosine phosphatase domains. EYA4 has been associated with several human
-
Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study Mol. Cancer (IF 37.3) Pub Date : 2023-09-28 Fuqiang Zhao, Ping Bai, Jianfeng Xu, Zitong Li, Shan Muhammad, Diange Li, Zeyue Zhang, Yibo Gao, Qian Liu
Although colonoscopy is the standard screening test for colorectal cancer (CRC), its use is limited by a poor compliance rate, the need for extensive bowel preparation, and the risk of complications. As an alternative, an FDA-approved stool-based DNA test, Cologuard, has demonstrated satisfactory detection performance for CRC, but its compliance rate remains suboptimal, primarily attributable to individuals’
-
Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency Mol. Cancer (IF 37.3) Pub Date : 2023-09-20 Jong-Wan Kwon, Jeong-Seop Oh, Sang Hyeok Seok, Hyeok-Won An, Yu Jin Lee, Na Yun Lee, Taehun Ha, Hyeon Ah Kim, Gyeong Min Yoon, Sung Eun Kim, Pu-Reum Oh, Su-Hyung Lee, Dominic C. Voon, Dae-Yong Kim, Jun Won Park
Targetable molecular drivers of gastric cancer (GC) metastasis remain largely unidentified, leading to limited targeted therapy options for advanced GC. We aimed to identify molecular drivers for metastasis and devise corresponding therapeutic strategies. We performed an unbiased in vivo genome-wide CRISPR/Cas9 knockout (KO) screening in peritoneal dissemination using genetically engineered GC mouse
-
Correction: Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation Mol. Cancer (IF 37.3) Pub Date : 2023-09-20 Feng Yang, Anpei Hu, Dan Li, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Xiaojing Wang, Kai Huang, Liduan Zheng, Qiangsong Tong
Correction: Mol Cancer 18, 158 (2019) https://doi.org/10.1186/s12943-019-1094-z Following publication of the original article [1], the authors identified errors in Fig. 2f and in Fig. 5h. In Fig. 5h, the transwell invasion images for “AGS Mock + circ-Mock”, “AGS Mock + circ-HuR”, and “MKN-45 Mock + circ-Mock” were misused. After a self-investigation and carefully check of the archived images of this
-
Correction: Advances in immunotherapy for triple-negative breast cancer Mol. Cancer (IF 37.3) Pub Date : 2023-09-14 Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu
Correction: Mol Cancer 22, 145 (2023) https://doi.org/10.1186/s12943-023-01850-7 Following the publication of the original article [1], the authors Yang Liu, Yueting Hu and Jinqi Xue are all the first author who contributed equally to the manuscript, however, the sentence ”Yang Liu, Yueting Hu and Jinqi Xue contributed equally to this work” is missing in the published version. The missing sentence
-
Retraction Note: HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail Mol. Cancer (IF 37.3) Pub Date : 2023-09-13 Bo Tang, Guangying Qi, Xiaoyu Sun, Fang Tang, Shengguang Yuan, Zhenran Wang, Xingsi Liang, Bo Li, Shuiping Yu, Jie Liu, Qi Huang, Yangchao Wei, Run Zhai, Biao Lei, Xinjin Guo, Songqing He
Retraction Note: Mol Cancer 15 , 57 (2016) https://doi.org/10.1186/s12943-016-0540-4 The Editor-in-Chief has retracted this article at the authors’ request. After publication, concerns were raised regarding multiple cases of H&E staining and western blot image overlap with other articles that were submitted and published within a close time frame [1,2,3,4,5,6,7,8]. The authors have stated that the
-
circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer Mol. Cancer (IF 37.3) Pub Date : 2023-09-09 Zhongjie Zhao, Wenbo Yang, Rui Kong, Yangyang Zhang, Le Li, Zengfu Song, Hongze Chen, Yan Luo, Tao Zhang, Chundong Cheng, Guanqun Li, Danxi Liu, Xinglong Geng, Hua Chen, Yongwei Wang, Shangha Pan, Jisheng Hu, Bei Sun
Among digestive tract tumours, pancreatic ductal adenocarcinoma (PDAC) shows the highest mortality trend. Moreover, although PDAC metastasis remains a leading cause of cancer-related deaths, the biological mechanism is poorly understood. Recent evidence demonstrates that circular RNAs (circRNAs) play important roles in PDAC progression. Differentially expressed circRNAs in normal and PDAC tissues were
-
CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer Mol. Cancer (IF 37.3) Pub Date : 2023-09-08 Bo Xie, Juntao Lin, Xianwu Chen, Xuejian Zhou, Yan Zhang, Mengjing Fan, Jiayong Xiang, Ning He, Zhenghui Hu, Feifan Wang
Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular RNAs. In the current study, our findings showed that circXRN2 suppresses tumor progression driven by histone lactylation by activating the Hippo pathway in human bladder cancer. RNA immunoprecipitation
-
Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies Mol. Cancer (IF 37.3) Pub Date : 2023-09-07 Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak, Katarzyna Magiera-Mularz
Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway continues to lead to the testing of multiple approaches and optimizations. Recently, a series of macrocyclic peptides have been developed that exhibit binding
-
Should I stay or should I go? Spatio-temporal control of cellular anchorage by hematopoietic factors orchestrates tumor metastatic cascade Mol. Cancer (IF 37.3) Pub Date : 2023-09-07 Veronica Marabitti, Ignazio Caruana, Francesca Nazio
The term “metastatic cascade” defines a process whereby few tumor cells complete a sequence of steps to leave the primary tumor to reach one or more sites elsewhere in the body, usually through the bloodstream to develop one or several metastases. Due to the nature and plasticity of cancer, unfortunately no specific and functional anti-metastatic drugs are available. In this Commentary, we are highlighting
-
The evolution and heterogeneity of neutrophils in cancers: origins, subsets, functions, orchestrations and clinical applications Mol. Cancer (IF 37.3) Pub Date : 2023-09-07 Siyao Liu, Wenchuan Wu, Yueshan Du, Hanlin Yin, Qiangda Chen, Weisheng Yu, Wenquan Wang, Jun Yu, Liang Liu, Wenhui Lou, Ning Pu
Neutrophils, the most prevalent innate immune cells in humans, have garnered significant attention in recent years due to their involvement in cancer progression. This comprehensive review aimed to elucidate the important roles and underlying mechanisms of neutrophils in cancer from the perspective of their whole life cycle, tracking them from development in the bone marrow to circulation and finally
-
Clinically conserved genomic subtypes of gastric adenocarcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-09-06 Yun Seong Jeong, Young-Gyu Eun, Sung Hwan Lee, Sang-Hee Kang, Sun Young Yim, Eui Hyun Kim, Joo Kyung Noh, Bo Hwa Sohn, Seon Rang Woo, Moonkyoo Kong, Deok Hwa Nam, Hee-Jin Jang, Hyun-Sung Lee, Shumei Song, Sang Cheul Oh, Jeeyun Lee, Jaffer A. Ajani, Ju-Seog Lee
Gastric adenocarcinoma (GAC) is a lethal disease characterized by genomic and clinical heterogeneity. By integrating 8 previously established genomic signatures for GAC subtypes, we identified 6 clinically and molecularly distinct genomic consensus subtypes (CGSs). CGS1 have the poorest prognosis, very high stem cell characteristics, and high IGF1 expression, but low genomic alterations. CGS2 is enriched
-
Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells Mol. Cancer (IF 37.3) Pub Date : 2023-09-04 Neha Khera, Asvika Soodhalaagunta Rajkumar, Khlood Abdulkader M Alkurdi, Zhiao Liu, Hong Ma, Ahmad Waseem, Muy-Teck Teh
Multidrug resistance renders treatment failure in a large proportion of head and neck squamous cell carcinoma (HNSCC) patients that require multimodal therapy involving chemotherapy in conjunction with surgery and/or radiotherapy. Molecular events conferring chemoresistance remain unclear. Through transcriptome datamining, 28 genes were subjected to pharmacological and siRNA rescue functional assays
-
Advances in immunotherapy for triple-negative breast cancer Mol. Cancer (IF 37.3) Pub Date : 2023-09-02 Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu
Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor cells and increases the tumoricidal effect of immune cells. It also suppresses immunosuppressive molecules, activates or restores immune system function, enhances anti-tumor immune responses
-
Correction: Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells Mol. Cancer (IF 37.3) Pub Date : 2023-09-02 Zhenlong Yu, Wei Guo, Xiaochi Ma, Baojing Zhang, Peipei Dong, Lin Huang, Xiuli Wang, Chao Wang, Xiaokui Huo, Wendan Yu, Canhui Yi, Yao Xiao, Wenjing Yang, Yu Qin, Yuhui Yuan, Songshu Meng, Quentin Liu, Wuguo Deng
Correction: Mol Cancer 13, 203 (2014) https://doi.org/10.1186/1476-4598-13-203 Unfortunately, the original version of this article [1] contained some errors. The words “binding” has been spelt incorrectly in the fifth title of result section and legend of Fig. 5. And the image of GAPDH (Fig. 6D) has been mistakenly uploaded. The mistakes did not affect any correctness of our results or discussion.
-
BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours Mol. Cancer (IF 37.3) Pub Date : 2023-08-30 Qin Yu, Wenhao Fu, Yutang Fu, Wenjing Ye, Huiqiong Yan, Zecheng Yu, Ruirui Li, Yili Cai, Yuxin Chen, Lingyun Wang, Xianqiao Wei, Yangkun Chen, Yuheng Zhang, Huazhong Ying, Furong Tang, Fangwei Dai, Wei Han
Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated
-
Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy Mol. Cancer (IF 37.3) Pub Date : 2023-08-30 Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocío Granda-Díaz, Alejandra Martínez-Pérez, Candelaria Aguilar-García, Juan P. Rodrigo, Juana M. García-Pedrero, Segundo Gonzalez
Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, the limited overall responses and lack of reliable predictive biomarkers of patient´s response are major pitfalls
-
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells Mol. Cancer (IF 37.3) Pub Date : 2023-08-30 Jiangping Li, Zhiwen Xiao, Donghui Wang, Lei Jia, Shihong Nie, Xingda Zeng, Wei Hu
Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid tumors. With the development of next-generation sequencing and bioinformatics technology, the rapid identification and prediction of tumor-specific antigens (TSAs) has become possible. Compared
-
Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-08-19 Lingbo An, Mingyang Li, Qingge Jia
Esophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-related mortality worldwide, with more than half of them occurred in China. Radiotherapy (RT) has been widely used for treating ESCC. However, radiation-induced DNA damage response (DDR) can promote the release of cytokines and chemokines, and triggers inflammatory reactions and changes in the tumor microenvironment
-
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance Mol. Cancer (IF 37.3) Pub Date : 2023-08-19 Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding, Jian Ding, Hua Xie
Correction: Mol Cancer 19, 90 (2020) https://doi.org/10.1186/s12943-020-01202-9 Following publication of the original article [1], the authors do notice that they mis-claimed the qRT-PCR primers that predicted to target human CDH10 gene as specific primers targeting human BIM gene in Materials and methods section when describing quantitative RT-PCR, and the primers have been mis-used to detect mRNA
-
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Mol. Cancer (IF 37.3) Pub Date : 2023-08-18 Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, Daniel B. L. Teh, Gautam Sethi, Vincenzo Cavalieri, Kevin H. Lin, Nathalie R. Javidi-Sharifi, Eneda Toska, Matthew S. Davids, Jennifer R. Brown, Patrizia
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer
-
m6A-regulated tumor glycolysis: new advances in epigenetics and metabolism Mol. Cancer (IF 37.3) Pub Date : 2023-08-15 Shi-Wei Yue, Hai-Ling Liu, Hong-Fei Su, Chu Luo, Hui-Fang Liang, Bi-Xiang Zhang, Wei Zhang
Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-proliferation, angiogenesis and lymphangiogenesis, metastasis, and also affect the immune escape, prognosis evaluation and therapeutic effect of cancer. The n6-methyladenosine (m6A) modification of RNA
-
Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors Mol. Cancer (IF 37.3) Pub Date : 2023-08-15 Paweł Stachura, Wei Liu, Haifeng C. Xu, Agnès Wlodarczyk, Olivia Stencel, Piyush Pandey, Melina Vogt, Sanil Bhatia, Daniel Picard, Marc Remke, Karl S. Lang, Dieter Häussinger, Bernhard Homey, Philipp A. Lang, Arndt Borkhardt, Aleksandra A. Pandyra
New therapies are urgently needed in melanoma, particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. To uncover novel potentiators of T cell anti-tumor immunity, we carried out an ex vivo pharmacological screen and identified 5-Nonyloxytryptamine (5-NL), a serotonin agonist, as increasing the ability of T cells to target tumor cells. The pharmacological screen
-
Correction: Reprogramming anchorage dependency by adherent‑to‑suspension transition promotes metastatic dissemination Mol. Cancer (IF 37.3) Pub Date : 2023-08-14 Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa‑Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh, Han‑Woong Lee, Kun‑Liang Guan, Yu Suk Choi, Joon Jeong, Junjeong Choi, Jae‑Seok Roe, Heon Yung Gee, Hyun Woo Park
Correction: Mol Cancer 22, 63 (2023) https://doi.org/10.1186/s12943-023-01753-7. Following publication of the original article [1], the author reported that the below Methods section needs to be added to the body text. Bioinformatics of published human cell line RNA-seq data analyses RNA-seq fastq files were obtained from the ENCODE database. CLC Genomics Workbench 9.5.3 software (Qiagen, Germany)
-
Correction: CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma Mol. Cancer (IF 37.3) Pub Date : 2023-08-12 Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan, Yong Zeng
Correction: Mol Cancer 21, 18 (2022) https://doi.org/10.1186/s12943-021-01482-9 Following publication of the original article [1], it has come to the authors’ attention that the image in Fig. 6F (the HuCCT1-sicNFIB group) appears to be doubled over itself possibly caused by an error during the microscopic image acquisition process. To avoid any confusion, we re-uploaded a clear version of this image
-
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway Mol. Cancer (IF 37.3) Pub Date : 2023-08-12 Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Gröschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolína Trachtová, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer, Anna Orlova, Nadine Witzeneder, Thomas Dillinger, Elisa Redl, Georg Greiner, David D’Andrea, Johnny R. Östman, Simone Tangermann, Ivana
Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the most frequently deleted genes in mPCa. Here we show a frequent genomic co-deletion of PTEN and STAT3 in liquid biopsies of patients with mPCa. Loss of Stat3 in a Pten-null mouse prostate model leads
-
Retraction Note: N6-methyladenosine induced mir-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1 Mol. Cancer (IF 37.3) Pub Date : 2023-08-12 Hongsheng Wang, Qianqian Deng, Ziyan Lv, Yuyi Ling, Xue Hou, Zhuojia Chen, Xiaoxiao Dinglin, Shuxiang Ma, Delan Li, Yingmin Wu, Yanxi Peng, Hongbing Huang, Likun Chen
Retraction note: Mol Cancer 18, 181 (2019). https://doi.org/10.1186/s12943-019-1108-x. The Editor-in-Chief has retracted this article at the First Authors’s request. After publication, concerns were raised regarding highly similar images in the figures. Specifically: Fig, 2F H1975 Con and Fig. 5I VASH1-C169A Con images appear to overlap. Figure 4C Vector and Vector + rVEGFA images appear to overlap